Physician profile
Morgan Hebert
NPI 1669193298
$6,194.26
in general payments reported to CMS, 2019-2025
36 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $2,165 · 2024: $1,889 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,053.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,538.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $697.04 | 2022-2025 | Farxiga, Breztri |
| Pfizer INC. | $454.40 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $436.10 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $419.80 | 2023-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $392.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $254.30 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $179.71 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.20 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $160.11 | 2023-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $123.43 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $115.07 | 2023-2025 | Rexulti |
| Ardelyx, INC. | $109.23 | 2023-2025 | Ibsrela |
| Exact Sciences Corporation | $107.76 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.20 | 2023-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $90.06 | 2023-2024 | Veozah |
| Viatris Specialty LLC | $79.49 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $78.77 | 2024-2025 | |
| Lundbeck LLC | $65.08 | 2023-2024 | Rexulti |
| Kestra Medical Technology Services, INC. | $63.37 | 2022-2023 | Assure Wcd |
| Idorsia Pharmaceuticals US INC | $63.26 | 2023-2024 | Quviviq |
| Alkermes, INC. | $60.98 | 2023-2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $60.05 | 2023-2024 | |
| Axsome Therapeutics, INC. | $59.39 | 2023-2025 | Auvelity |
| Mylan Specialty L.P. | $57.57 | 2022-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $57.47 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.92 | 2024-2025 | Xifaxan |
| Valinor Pharma, LLC | $37.45 | 2023-2025 | Movantik |
| Verona Pharma, INC. | $23.54 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $18.71 | 2025 | Nuzyra, Xhance |
| Fresenius USA Marketing, INC. | $17.35 | 2024 | Velphoro |
| Janssen Biotech, INC. | $14.73 | 2025 | Simponi, Simponi Aria, Stelara |
| Vanda Pharmaceuticals INC. | $14.17 | 2024 | Hetlioz, Fanapt |
| Ironwood Pharmaceuticals, INC | $13.81 | 2025 | |
| Amgen INC. | $13.40 | 2024 | Otezla, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.35 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.